| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3216 |
| Trial ID | NCT05590221 |
| Disease | B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Axi-Cel|Relma-cel|Axicabtagene Ciloleucel|JWCAR029|relmacabtagene autoleucel|Yescarta |
| Location approved | China |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Not Recruiting |
| Title | Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma |
| Year | 2022 |
| Country | China |
| Company sponsor | Peking University Cancer Hospital & Institute |
| Other ID(s) | JWCAR029011 |
| Cohort 1 | |||||||||||||
|
|||||||||||||